Evidence map›Paper›PMID 39698883›Full record

ArticleCurrent pharmaceutical design2025

Network Pharmacology and

Md Abul Bashar, Md Arju Hossain, Md Reduanul Haque Kavey, Rayhanuzzaman Shazib, Md Shofiqul Islam, Siddique Akber Ansari, Md Habibur Rahman

Abstract read
PubMed Publisher
In one paragraph

Article in Current pharmaceutical design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Md Abul BasharDepartment of Pharmacy, Faculty of Biological Sciences, Islamic University, Kushtia 7003, Bangladesh.ORCID 0000-0002-9933-7070
Md Arju HossainDepartment of Biotechnology and Genetic Engineering, Mawlana Bhashani Science and Technology University, Santosh, Tangail 1902, Bangladesh.
Md Reduanul Haque KaveyDepartment of Pharmacy, Faculty of Biological Sciences, Islamic University, Kushtia 7003, Bangladesh.ORCID 0009-0005-9964-423X
Rayhanuzzaman ShazibDepartment of Pharmacy, Faculty of Biological Sciences, Islamic University, Kushtia 7003, Bangladesh.ORCID 0009-0006-0442-3328
Md Shofiqul IslamInstitute for Intelligent Systems Research and Innovation (IISRI), Deakin University, 75 Pigdons Rd, Warunponds, Victoria 3216, Australia.
Siddique Akber AnsariDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O Box 2457, Riyadh 11451, Saudi Arabia.
Md Habibur RahmanDepartment of Computer Science and Engineering, Islamic University, Kushtia 7003, Bangladesh.

Funding

King Saud University, Riyadh, Saudi Arabia RSPD2024R744
6 · The paper itself

Abstract

backgroundAbout 10-15% of all breast cancers comprise triple-negative breast cancer (TNBC), defined as cancer cells that lack ER, PR, and HER2 protein receptors. Due to the absence of these receptors, treating TNBC using conventional chemotherapy is challenging and, therefore, requires the discovery of novel chemotherapeutic agents derived from natural sources.

objectiveThe current work was intended to study the potential phytochemicals of Ajwa dates (

methodsWe harnessed network pharmacology, molecular docking, drug-likeness studies, Molecular Dynamics (MD) simulation, and binding free energy (MM-GBSA) calculation to get phytochemicals with potential effects against TNBC. Firstly, molecular docking was performed on 125 phytochemicals against the Akt and PI3K proteins utilizing PyRx. Then, the phytochemicals with the highest binding affinity (≤ -8.1 kcal/mol) were examined for

resultsThe results of the network pharmacology revealed that the Akt and PI3K proteins are potential targets of TNBC for the phytochemicals of

conclusionTaken together, the current work emphasizes the potential effects of Daidzein from

Indexed as

Antineoplastic Agents, PhytogenicNetwork PharmacologyPhoeniceaePhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsPhytochemicalsPlant ExtractsProtein Kinase InhibitorsProto-Oncogene Proteins c-aktTriple Negative Breast NeoplasmsComputer SimulationFemaleHumansMolecular Docking SimulationMolecular Dynamics SimulationAntineoplastic Agents, PhytogenicPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsPhytochemicalsPlant ExtractsProtein Kinase InhibitorsProto-Oncogene Proteins c-aktdrug likenessGO pathwayhub genesKEGG pathwaymolecular dockingmolecular dynamics (MD) simulation.Phoenix dactylifera L.phosphoinositide 3-kinase (PI3K)phytochemicalsprotein kinase B (Akt)protein-protein interactionstriple-negative breast cancer (TNBC)

Identifiers

PMID39698883

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.